Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.

Xing C, Zhao H, Zhang J, He B

Frontiers in endocrinology17 Aug 2022Cited by 50 (Europe PMC)

PMID36060969PMCIDPMC9428699DOI10.3389/fendo.2022.945609PepBankPUB-36060969

Summary

ObjectiveTo observe the effect of metformin (MET) monotherapy versus MET plus liraglutide (LIRA) on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome (PCOS).MethodsSixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy. Anthropometric measurements, menstrual cycle changes, gonadal profiles, and oral glucose tolerance tests (OGTT) were conducted at baseline and after the 12-week treatment.ResultsFifty-two subjects completed the trial while eight were lost during the follow-up. Both MET and COM improved menstrual cycles, anthropometric parameters, and glucose metabolism after the 12-week treatment; however, there was no statistical difference between the two groups. MET plus LIRA therapy improved hyperandrogenemia, including TT (total testosterone), SHBG (sex hormone binding globulin) and FAI (free androgen index), whereas MET monotherapy only improved SHBG and FAI when compared with baseline. Furthermore, both MET monotherapy and MET plus LIRA therapy improved E2 (estradiol) while only MET plus LIRA therapy improved LH (luteinizing hormone), FSH (follicle stimulating hormone) and Prog (progesterone) more effectively than baseline. Additionally, MET plus LIRA therapy may improve TT, SHBG, FAI, LH and Prog more effectively than MET monotherapy; however, there were no significant differences on E2, FSH and LH/FSH between the two groups.ConclusionsIn overweight patients with PCOS, both MET monotherapy and MET plus LIRA therapy improved glucose metabolism and relieved insulin resistance (IR). Additionally, MET plus LIRA therapy was more effective than MET monotherapy in improving reproductive abnormalities and hyperandrogenemia, potentially by modulating the hypothalamic-pituitary-ovarian axis.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study21

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, menstrual cycle improvement did not differ statistically between metformin plus liraglutide and metformin alone.
In plain wordsIn overweight patients with PCOS, menstrual cycles improved to a similar degree with metformin plus liraglutide and with metformin alone.
Peptide
Liraglutide
Outcome
No significant changeMenstrual cycle improvement, metformin plus liraglutide versus metformin
Study
n = 52
Comparator
Metformin monotherapy
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Both MET and COM improved menstrual cycles, anthropometric parameters, and glucose metabolism after the 12-week treatment; however, there was no statistical difference between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
Show in the study text Report a problemFND-3606096901
02HumanRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, improvement in anthropometric parameters did not differ statistically between metformin plus liraglutide and metformin alone.
In plain wordsIn overweight patients with PCOS, body measures improved to a similar degree with metformin plus liraglutide and with metformin alone.
Peptide
Liraglutide
Outcome
No significant changeAnthropometric parameters, metformin plus liraglutide versus metformin
Study
n = 52
Comparator
Metformin monotherapy
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Both MET and COM improved menstrual cycles, anthropometric parameters, and glucose metabolism after the 12-week treatment; however, there was no statistical difference between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
Show in the study text Report a problemFND-3606096902
03HumanRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, improvement in glucose metabolism did not differ statistically between metformin plus liraglutide and metformin alone.
In plain wordsIn overweight patients with PCOS, glucose control improved to a similar degree with metformin plus liraglutide and with metformin alone.
Peptide
Liraglutide
Outcome
No significant changeGlucose metabolism, metformin plus liraglutide versus metformin
Study
n = 52
Comparator
Metformin monotherapy
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Both MET and COM improved menstrual cycles, anthropometric parameters, and glucose metabolism after the 12-week treatment; however, there was no statistical difference between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
Show in the study text Report a problemFND-3606096903
04HumanRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, metformin plus liraglutide may improve total testosterone more effectively than metformin alone.
In plain wordsIn overweight patients with PCOS, metformin plus liraglutide may improve testosterone levels more than metformin alone.
Peptide
Liraglutide
Outcome
Direction not reportedTotal testosterone, metformin plus liraglutide versus metformin
Study
n = 52
Comparator
Metformin monotherapy
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Additionally, MET plus LIRA therapy may improve TT, SHBG, FAI, LH and Prog more effectively than MET monotherapy; however, there were no significant differences on E2, FSH and LH/FSH between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
Show in the study text Report a problemFND-3606096904
05HumanRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, metformin plus liraglutide may improve sex hormone binding globulin more effectively than metformin alone.
In plain wordsIn overweight patients with PCOS, metformin plus liraglutide may improve a hormone-carrying protein more than metformin alone.
Peptide
Liraglutide
Outcome
Direction not reportedSHBG, metformin plus liraglutide versus metformin
Study
n = 52
Comparator
Metformin monotherapy
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Additionally, MET plus LIRA therapy may improve TT, SHBG, FAI, LH and Prog more effectively than MET monotherapy; however, there were no significant differences on E2, FSH and LH/FSH between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
Show in the study text Report a problemFND-3606096905
06HumanRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, metformin plus liraglutide may improve the free androgen index more effectively than metformin alone.
In plain wordsIn overweight patients with PCOS, metformin plus liraglutide may improve a male-hormone index more than metformin alone.
Peptide
Liraglutide
Outcome
Direction not reportedFree androgen index, metformin plus liraglutide versus metformin
Study
n = 52
Comparator
Metformin monotherapy
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Additionally, MET plus LIRA therapy may improve TT, SHBG, FAI, LH and Prog more effectively than MET monotherapy; however, there were no significant differences on E2, FSH and LH/FSH between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
Show in the study text Report a problemFND-3606096906
07HumanRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, metformin plus liraglutide may improve luteinizing hormone more effectively than metformin alone.
In plain wordsIn overweight patients with PCOS, metformin plus liraglutide may improve luteinizing hormone levels more than metformin alone.
Peptide
Liraglutide
Outcome
Direction not reportedLuteinizing hormone, metformin plus liraglutide versus metformin
Study
n = 52
Comparator
Metformin monotherapy
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Additionally, MET plus LIRA therapy may improve TT, SHBG, FAI, LH and Prog more effectively than MET monotherapy; however, there were no significant differences on E2, FSH and LH/FSH between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
Show in the study text Report a problemFND-3606096907
08HumanRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, metformin plus liraglutide may improve progesterone more effectively than metformin alone.
In plain wordsIn overweight patients with PCOS, metformin plus liraglutide may improve progesterone levels more than metformin alone.
Peptide
Liraglutide
Outcome
Direction not reportedProgesterone, metformin plus liraglutide versus metformin
Study
n = 52
Comparator
Metformin monotherapy
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Additionally, MET plus LIRA therapy may improve TT, SHBG, FAI, LH and Prog more effectively than MET monotherapy; however, there were no significant differences on E2, FSH and LH/FSH between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
Show in the study text Report a problemFND-3606096908
09HumanRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, estradiol did not differ significantly between metformin plus liraglutide and metformin alone.
In plain wordsIn overweight patients with PCOS, estradiol levels did not differ between metformin plus liraglutide and metformin alone.
Peptide
Liraglutide
Outcome
No significant changeEstradiol, metformin plus liraglutide versus metformin
Study
n = 52
Comparator
Metformin monotherapy
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Additionally, MET plus LIRA therapy may improve TT, SHBG, FAI, LH and Prog more effectively than MET monotherapy; however, there were no significant differences on E2, FSH and LH/FSH between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
Show in the study text Report a problemFND-3606096909
10HumanRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, follicle stimulating hormone did not differ significantly between metformin plus liraglutide and metformin alone.
In plain wordsIn overweight patients with PCOS, follicle stimulating hormone did not differ between metformin plus liraglutide and metformin alone.
Peptide
Liraglutide
Outcome
No significant changeFSH, metformin plus liraglutide versus metformin
Study
n = 52
Comparator
Metformin monotherapy
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Additionally, MET plus LIRA therapy may improve TT, SHBG, FAI, LH and Prog more effectively than MET monotherapy; however, there were no significant differences on E2, FSH and LH/FSH between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
Show in the study text Report a problemFND-3606096910
11HumanRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, the LH/FSH ratio did not differ significantly between metformin plus liraglutide and metformin alone.
In plain wordsIn overweight patients with PCOS, the LH/FSH ratio did not differ between metformin plus liraglutide and metformin alone.
Peptide
Liraglutide
Outcome
No significant changeLH/FSH ratio, metformin plus liraglutide versus metformin
Study
n = 52
Comparator
Metformin monotherapy
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Additionally, MET plus LIRA therapy may improve TT, SHBG, FAI, LH and Prog more effectively than MET monotherapy; however, there were no significant differences on E2, FSH and LH/FSH between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
Show in the study text Report a problemFND-3606096911

Studies that did not test the peptide alone10

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

12HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, metformin plus liraglutide improved menstrual cycles after 12 weeks versus baseline.
In plain wordsIn overweight patients with PCOS, menstrual cycles improved after 12 weeks of metformin plus liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedMenstrual cycle after metformin plus liraglutide
Study
n = 52
Comparator
Baseline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Both MET and COM improved menstrual cycles, anthropometric parameters, and glucose metabolism after the 12-week treatment; however, there was no statistical difference between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3606096912
13HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, metformin plus liraglutide improved anthropometric parameters after 12 weeks versus baseline.
In plain wordsIn overweight patients with PCOS, body measures improved after 12 weeks of metformin plus liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedAnthropometric parameters after metformin plus liraglutide
Study
n = 52
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Both MET and COM improved menstrual cycles, anthropometric parameters, and glucose metabolism after the 12-week treatment; however, there was no statistical difference between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3606096913
14HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, metformin plus liraglutide improved glucose metabolism after 12 weeks versus baseline.
In plain wordsIn overweight patients with PCOS, glucose control improved after 12 weeks of metformin plus liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedGlucose metabolism after metformin plus liraglutide
Study
n = 52
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Both MET and COM improved menstrual cycles, anthropometric parameters, and glucose metabolism after the 12-week treatment; however, there was no statistical difference between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3606096914
15HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, metformin plus liraglutide improved total testosterone versus baseline.
In plain wordsIn overweight patients with PCOS, testosterone levels improved after metformin plus liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedTotal testosterone after metformin plus liraglutide
Study
n = 52
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
MET plus LIRA therapy improved hyperandrogenemia, including TT (total testosterone), SHBG (sex hormone binding globulin) and FAI (free androgen index), whereas MET monotherapy only improved SHBG and FAI when compared with baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3606096915
16HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, metformin plus liraglutide improved sex hormone binding globulin versus baseline.
In plain wordsIn overweight patients with PCOS, a hormone-carrying protein improved after metformin plus liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedSHBG after metformin plus liraglutide
Study
n = 52
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
MET plus LIRA therapy improved hyperandrogenemia, including TT (total testosterone), SHBG (sex hormone binding globulin) and FAI (free androgen index), whereas MET monotherapy only improved SHBG and FAI when compared with baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3606096916
17HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, metformin plus liraglutide improved the free androgen index versus baseline.
In plain wordsIn overweight patients with PCOS, a male-hormone index improved after metformin plus liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedFree androgen index after metformin plus liraglutide
Study
n = 52
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
MET plus LIRA therapy improved hyperandrogenemia, including TT (total testosterone), SHBG (sex hormone binding globulin) and FAI (free androgen index), whereas MET monotherapy only improved SHBG and FAI when compared with baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3606096917
18HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, metformin plus liraglutide improved estradiol versus baseline.
In plain wordsIn overweight patients with PCOS, estradiol improved after metformin plus liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedEstradiol after metformin plus liraglutide
Study
n = 52
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Furthermore, both MET monotherapy and MET plus LIRA therapy improved E2 (estradiol) while only MET plus LIRA therapy improved LH (luteinizing hormone), FSH (follicle stimulating hormone) and Prog (progesterone) more effectively than baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3606096918
19HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, only metformin plus liraglutide improved luteinizing hormone more effectively than baseline.
In plain wordsIn overweight patients with PCOS, luteinizing hormone improved after metformin plus liraglutide but not after metformin alone.
Peptide
Liraglutide
Outcome
Direction not reportedLuteinizing hormone after metformin plus liraglutide
Study
n = 52
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Furthermore, both MET monotherapy and MET plus LIRA therapy improved E2 (estradiol) while only MET plus LIRA therapy improved LH (luteinizing hormone), FSH (follicle stimulating hormone) and Prog (progesterone) more effectively than baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3606096919
20HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, only metformin plus liraglutide improved follicle stimulating hormone more effectively than baseline.
In plain wordsIn overweight patients with PCOS, follicle stimulating hormone improved after metformin plus liraglutide but not after metformin alone.
Peptide
Liraglutide
Outcome
Direction not reportedFSH after metformin plus liraglutide
Study
n = 52
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Furthermore, both MET monotherapy and MET plus LIRA therapy improved E2 (estradiol) while only MET plus LIRA therapy improved LH (luteinizing hormone), FSH (follicle stimulating hormone) and Prog (progesterone) more effectively than baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3606096920
21HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In overweight patients with PCOS, only metformin plus liraglutide improved progesterone more effectively than baseline.
In plain wordsIn overweight patients with PCOS, progesterone improved after metformin plus liraglutide but not after metformin alone.
Peptide
Liraglutide
Outcome
Direction not reportedProgesterone after metformin plus liraglutide
Study
n = 52
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Furthermore, both MET monotherapy and MET plus LIRA therapy improved E2 (estradiol) while only MET plus LIRA therapy improved LH (luteinizing hormone), FSH (follicle stimulating hormone) and Prog (progesterone) more effectively than baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight patients with PCOS were recruited from January 2021 to January 2022 in Shengjing Hospital of China Medical University and were randomly assigned to the MET or combination (COM) group to receive 12 weeks of MET monotherapy or MET plus LIRA therapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3606096921

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT05702905

Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome

Peking University First Hospitaln = 759 May 2023 to est. 30 Jun 2025

PCOS (Polycystic Ovary Syndrome) · Semaglutide

Trial page ClinicalTrials.govUpdated 25 Mar 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.